Breast Cancer Genetics: New Mutations Beyond BRCA Linked to Many Indian Cases

The Alarming Rise of Breast Cancer in India

Breast cancer has become the leading cancer among women in India, accounting for 28.2% of all female cancers. According to recent data from state cancer registries, more women—43,163—were diagnosed in 2021 compared to 33,805 men across all cancers, highlighting the disproportionate burden on women. The age-adjusted incidence rate has more than doubled from 13 per 100,000 women in 1990 to 29.4 per 100,000 in 2023, with projections indicating a continued rise driven by lifestyle changes, urbanization, and an aging population. Mortality rates have also climbed 74%, from 8.9 to 15.5 per 100,000, underscoring the need for better early detection and targeted interventions.

In urban areas, the incidence reaches up to 30 per 100,000, while rural rates hover around 5 per 100,000 annually. The Indian Council of Medical Research (ICMR) estimates around 144,000 new cases yearly, with a 5.6% annual increase expected. Notably, Indian women often present with breast cancer at younger ages—about a decade earlier than in Western countries—and with more aggressive subtypes like triple-negative breast cancer, complicating treatment.

Understanding Breast Cancer Genetics: Germline Mutations Explained

Breast cancer genetics revolves around germline mutations—inherited changes in DNA present in every cell from birth. These differ from somatic mutations, which occur only in tumor cells. While most breast cancers (90-95%) are sporadic, 5-10% stem from hereditary factors. BRCA1 (Breast Cancer gene 1) and BRCA2 (Breast Cancer gene 2) are the most famous, repairing DNA double-strand breaks via homologous recombination. Pathogenic variants in these genes raise lifetime breast cancer risk to 45-72% by age 70-80.

However, BRCA1/2 explain only a fraction of hereditary cases globally and even less in diverse populations like India. Non-BRCA genes, including moderate-penetrance ones like PALB2 (Partner and Localizer of BRCA2), CHEK2 (Checkpoint kinase 2), ATM (Ataxia-telangiectasia mutated), and high-penetrance TP53 (Tumor Protein p53), contribute significantly. These genes influence DNA repair, cell cycle control, and tumor suppression. In India, unique population-specific variants amplify their relevance, necessitating ancestry-tailored testing.

🧬 Breakthrough IIT Madras Study Reveals Hidden Risks

A landmark study led by researchers at the Indian Institute of Technology Madras (IIT Madras), in collaboration with Karkinos Healthcare, Kumaran Hospital, and Chennai Breast Centre, has reshaped our understanding of breast cancer genetics in India. Published in the peer-reviewed journal BMC Cancer and integrated into the Bharat Cancer Genome Atlas—India's premier open-source cancer genomics resource—the study analyzed germline whole-exome sequencing from 479 unselected breast cancer patients sourced from the National Cancer Tissue Biobank.BMC Cancer Study

Key revelation: 24.6% of patients carried pathogenic or likely pathogenic variants (P/LPV) in 97 cancer susceptibility genes. Shockingly, only 8.35% involved BRCA1/2, meaning two-thirds (67%) of positive findings lurked in non-BRCA genes. Professor S. Mahalingam, head of the biobank, emphasized: "This means two-thirds of risk-raising variants hide outside the famous BRCA1/BRCA2. Genetic testing in India focuses on these two genes or specific hotspots, so we miss most risks."

Key Non-BRCA Genes Fueling Indian Breast Cancer Cases

The study pinpointed variants in homologous recombination repair (HRR) pathway genes at 11.9% overall prevalence. Within HRR, BRCA2 dominated (36%), followed by BRCA1 (30%) and ATM (14%). Beyond HRR, standout non-BRCA genes included:

• MLH1 (3.5%): DNA mismatch repair gene, linked to Lynch syndrome and colorectal risks alongside breast.
• NF1 (2.7%): Regulates cell growth; mutations cause neurofibromatosis type 1.
• TP53 (1.5%): Guardian of the genome; defines Li-Fraumeni syndrome with multi-cancer risks.
• RB1 (1.5%): Controls cell cycle; tied to retinoblastoma and secondary cancers.
• Others: PALB2, CHEK2, BARD1, and emerging like RECQL (India-enriched, rare globally).

Earlier Indian studies corroborate: Multi-gene panels in over 1,000 patients showed high TP53 and PALB2 rates post-BRCA. These genes elevate risk 20-85% lifetime, varying by variant and ethnicity.

Prevalence Breakdown and Demographic Insights

In the IIT Madras cohort, 24.6% total P/LPV equates to roughly 1 in 4 patients harboring inherited risk—far higher than BRCA-only estimates (10-15% globally). Non-BRCA accounted for ~16% of cases. Younger patients (<40 years) showed higher variant rates, aligning with India's trend of early-onset disease (median diagnosis ~47 years vs. 62 in US).

ICMR notes triple-negative subtypes (often BRCA1-linked) are 20-30% in India vs. 10-15% West, worsening prognosis.ICMR Breast Cancer Guidelines

Implications for Screening and Precision Medicine

Current BRCA-focused testing misses 67% of risks, per the study. Broader multi-gene panels (50-100 genes) or exome sequencing are urged, especially for unselected patients. Benefits include:

• Family cascade screening: Relatives of carriers gain early surveillance.
• Targeted therapies: PARP inhibitors (e.g., olaparib) for HRR-deficient tumors.
• Pharmacogenomics: DPYD variants (5%) predict severe 5-FU toxicity; pre-chemo genotyping saves lives.
• Secondary findings: 21.7% actionable non-cancer risks (e.g., cardiac arrhythmias, hypercholesterolemia).

Dr. Bani Jolly noted: "Routine DPYD tests before treatment are essential." India needs affordable panels (<₹20,000) and databases like Bharat Cancer Genome Atlas for South Asian variants.

Challenges Unique to India: Access, Awareness, and Affordability

Late-stage diagnosis (70% stage III/IV) stems from low awareness, rural-urban divides, and stigma. Genetic testing costs ₹15,000-50,000, inaccessible for most. Younger onset demands family history probing beyond BRCA. Cultural factors delay screening; ICMR recommends clinical exams over mammography for average-risk women.

Solutions: Government subsidies, AI-driven risk models, mobile clinics. Universities like IIT Madras pioneer biobanks, enabling large-scale studies.

University-Led Research Fueling India's Cancer Genomics Revolution

Indian institutes drive progress: IIT Madras' National Cancer Tissue Biobank powers datasets; Tata Memorial Centre sequences families; IISERs probe mechanisms. Collaborations with Karkinos yield Bharat Cancer Genome Atlas, open for global researchers. These efforts position India in precision oncology, training next-gen geneticists.

Explore research jobs in higher education or research assistant positions to contribute. For India-specific opportunities, check university jobs in India.

Future Outlook: Tailored Testing and Therapies

Upcoming: Expanded panels, liquid biopsies, AI variant classifiers. Trials for PARP in non-BRCA HRD tumors. Policy shifts toward universal germline testing in high-risk clinics. By 2030, economic burden could hit $14B; proactive genetics cuts this via prevention.

Stakeholders: ICMR, DBT fund studies; startups develop cheap sequencers.

Careers in Cancer Genetics: Opportunities in Indian Academia

India's genomics boom creates roles in bioinformatics, counseling, clinical trials. PhDs from IITs/IISc lead; postdocs analyze variants. Genetic counselors bridge labs-clinics. Platforms like higher-ed postdoc jobs, academic CV tips aid entry. Rate My Professor for mentors; higher-ed jobs for openings.

Actionable Advice for Patients and Families

• Assess family history: Multiple cases, young onset, bilateral? Test broadly.
• Seek NCCN/ICMR high-risk clinics at Tata Memorial, AIIMS.
• Lifestyle: Exercise, breastfeeding reduce risk 20-30%.
• Awareness: Monthly self-exams from 20s.

Consult geneticists; early action saves lives.

Photo by Harsh Vardhan Yadav on Unsplash

Wrapping Up: A Call for Comprehensive Genetic Strategies

The IIT Madras study illuminates non-BRCA mutations' dominance in Indian breast cancer genetics, urging paradigm shifts in testing. Universities spearhead this; join via university jobs, higher-ed jobs, career advice, rate professors. Precision genomics promises fewer tragedies.